

**MTN 028 - Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048**  
**Report - March 3, 2017**

**Visit Cutoff Date: December 9, 2016**

**. Retention by Visit and Site**

	<b>San Francisco</b>	<b>All Sites</b>
Participants Enrolled	19	19
<b>Day 1</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	19 (100%)	19 (100%)
Not Completed	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)
Not Expected	0	0
<b>Day 2</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	19 (100%)	19 (100%)
Not Completed	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)
Not Expected	0	0
<b>Day 3</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	19 (100%)	19 (100%)
Not Completed	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)
Not Expected	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 028 - Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048**  
**Report - March 3, 2017**

**Visit Cutoff Date: December 9, 2016**

**. Retention by Visit and Site**

	<b>San Francisco</b>	<b>All Sites</b>
<b>Day 7</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	19 (100%)	19 (100%)
Not Completed	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)
Not Expected	0	0
<b>Day 14</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	19 (100%)	19 (100%)
Not Completed	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)
Not Expected	0	0
<b>Day 21</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	18 (95%)	18 (95%)
Not Completed	1 (5%)	1 (5%)
Missed	0 (0%)	0 (0%)
Terminated Early	1 (5%)	1 (5%)
Not Expected	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 028 - Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048**  
**Report - March 3, 2017**

**Visit Cutoff Date: December 9, 2016**

**. Retention by Visit and Site**

	<b>San Francisco</b>	<b>All Sites</b>
<b>Day 28</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	18 (95%)	18 (95%)
Not Completed	1 (5%)	1 (5%)
Missed	0 (0%)	0 (0%)
Terminated Early	1 (5%)	1 (5%)
Not Expected	0	0
<b>Day 29</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	18 (95%)	18 (95%)
Not Completed	1 (5%)	1 (5%)
Missed	0 (0%)	0 (0%)
Terminated Early	1 (5%)	1 (5%)
Not Expected	0	0
<b>Day 30</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	18 (95%)	18 (95%)
Not Completed	1 (5%)	1 (5%)
Missed	0 (0%)	0 (0%)
Terminated Early	1 (5%)	1 (5%)
Not Expected	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 028 - Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048**  
**Report - March 3, 2017**

**Visit Cutoff Date: December 9, 2016**

**. Retention by Visit and Site**

	<b>San Francisco</b>	<b>All Sites</b>
<b>Day 31</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	18 (95%)	18 (95%)
Not Completed	1 (5%)	1 (5%)
Missed	0 (0%)	0 (0%)
Terminated Early	1 (5%)	1 (5%)
Not Expected	0	0
<b>Day 35/Final Clinic Visit</b>		
Expected <sup>2</sup>	19	19
Completed <sup>3</sup>	18 (95%)	18 (95%)
Not Completed	1 (5%)	1 (5%)
Missed	0 (0%)	0 (0%)
Terminated Early	1 (5%)	1 (5%)
Not Expected	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.